Original BioMedicals Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-75	-59.66	-40.28	-33.88	-34.75	Upgrade
Depreciation & Amortization	8.4	8.74	7.94	8.64	11.88	Upgrade
Stock-Based Compensation	0.77	6.72	0.34	-	0.22	Upgrade
Other Operating Activities	-0.05	-	-	-	-	Upgrade
Change in Accounts Receivable	-0.52	-0.09	0.04	-0.04	-	Upgrade
Change in Accounts Payable	-15.74	18.97	1.15	1.8	-1.13	Upgrade
Change in Other Net Operating Assets	-1.98	-2.17	0.38	-1.45	-0.18	Upgrade
Operating Cash Flow	-84.11	-27.5	-30.42	-24.93	-23.94	Upgrade
Capital Expenditures	-1.84	-0.31	-0.47	-1.92	-	Upgrade
Investment in Securities	10.06	-64.87	39.92	-74.85	-	Upgrade
Other Investing Activities	-	0.89	-0.17	-	-	Upgrade
Investing Cash Flow	8.22	-64.29	39.28	-76.77	-	Upgrade
Long-Term Debt Repaid	-4.26	-3.85	-3.35	-2.95	-2.77	Upgrade
Net Debt Issued (Repaid)	-4.26	-3.85	-3.35	-2.95	-2.77	Upgrade
Issuance of Common Stock	2.92	310.34	-	105.02	12	Upgrade
Financing Cash Flow	-1.34	306.49	-3.35	102.07	9.23	Upgrade
Net Cash Flow	-77.23	214.7	5.52	0.36	-14.72	Upgrade
Free Cash Flow	-85.95	-27.81	-30.89	-26.86	-23.94	Upgrade
Free Cash Flow Margin	-	-64674.42%	-28864.49%	-	-	Upgrade
Free Cash Flow Per Share	-1.30	-0.56	-0.66	-0.65	-0.87	Upgrade
Cash Interest Paid	0.87	1.1	1.2	1.39	1.57	Upgrade
Levered Free Cash Flow	-60.06	-5.75	-16.41	-14.23	-11.11	Upgrade
Unlevered Free Cash Flow	-59.52	-5.08	-15.66	-13.36	-10.13	Upgrade
Change in Net Working Capital	17.89	-16.82	-1.63	-0.34	1.15	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.